Richard J. Lim, M.B.A.

Rich’s career in the life science sector spans three decades demonstrating strategic and corporate development leadership within the biotech industry as well as investment leadership at top-performing venture capital firms. He is considered a trusted partner to visionary scientists and entrepreneurs, by being directly involved in the early capital raises of leading prominent biotech start-ups.

From 2020 to 2021, Rich served as Chief Business Officer and SVP of Corporate Development for an oncology focused biopharmaceutical company, where he led all deal-making activities including acquisitions, licensing, and partnerships. As a member of the senior executive team, Richard contributed to the company becoming one of the top 5 biopharma IPOs of 2020.

From 2008 to 2020, Rich served as a Managing Member and President of top quartile performing Omega Funds, where he sourced, conducted diligence, raised capital and served for many of Omega’s most successful portfolio companies. He served on the Board of Directors for Nuvation Bio (NASDAQ: NUVB), Gossamer Bio (NASDAQ: GOSS), and Replimune (NASDAQ: REPL) and Paratek Pharmaceuticals (NASDAQ: PRTK).

Previously, Rich was a Managing Director of MVM Life Science Partners LLP, where he founded MVM’s US operations and sourced all US deals during his tenure. Before MVM, Rich was Vice President at Saunders Karp & Megrue, a private equity firm, where he focused on healthcare equity deals. Rich was also Engagement Manager at LEK Consulting, a strategy and mergers & acquisitions consulting firm where he advised leading biotech and pharma companies.

Mr. Lim received his A.B. from Harvard College and M.B.A. from Harvard Business School.